What Happened to Sage Therapeutics Stock?
On June 15, shares of Sage Therapeutics (NASDAQ: SAGE) fell by as much as 20% in a single day after the company released phase 3 top-line data for zuranolone, an oral neuroactive steroid and GABA receptor modulator for the treatment of depression.
Even though the study met its primary endpoints, investors were not impressed by what they saw. So just what exactly is behind the bearish sentiment?
Image source: Getty Images.
Source Fool.com
